Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2021.

Subcategories:Axial SpondyloarthritisClinical Criteria/GuidelinesGout and Crystalline ArthritisMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis
Lisa Stamp, MBChB, PhD |
Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2021.
Lisa Rapaport |
(Reuters Health)—Nail salon drying lamps that emit ultraviolet (UV) light may contribute to periungual cutaneous lupus erythematosus lesions, according to case reports detailed in a recent publication.1 Exposure to the sun has long been linked to exacerbations of skin lupus, and, more recently, other types of light sources including surgical lamps have been connected to…
Additional training may be needed on the appearance of the maturing sacroiliac (SI) joint on MRI. In a recent study, researchers found local radiologists may mistake normal physiologic changes of a maturing SI joint as sacroiliitis in pediatric patients.
In early October, the FDA approved avacopan to treat anti-neutrophil cytoplasmic antibody associated vasculitis. Here are insights into the treatment’s risks and considerations.
Gendron et al. undertook this study to investigate the prevalence and prognostic value of conventional and nonconventional antiphospholipid antibodies in patients with COVID-19.
Ethan Craig, MD, MHS |
It feels like a long decade has passed since March 2020. At The Rheumatologist, we closed out 2020 with a special supplement on gout. Physician Editor Phil Seo, MD, MHS, kicked off that supplement with, “COVID-19. Black Lives Matter. A new gout guideline. These are some of the things 2020 ushered in. And we’re unlikely…
The use of objective, validated outcome measures to track progress in symptom control for patients with psoriatic arthritis was discussed in a session at the 2019 ACR/ARP Annual Meeting titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater insights into this topic and…
We are fortunate to have clinical practice guidelines for the management of psoriasis and psoriatic arthritis (PsA) from multiple organizations to help navigate today’s rapidly evolving therapeutic landscape. We are further fortunate to have multiple specialists to manage these conditions: rheumatologists and dermatologists. However, multiple guidelines, multiple drugs and multiple specialists can create a paradox…
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…
Sarah D. Bayefsky, MD, Kimberly DeQuattro, MD, & Rebecca E. Sadun, MD, PhD |
Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and…